Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

CLINUVEL's Annual Report for the year ended 30 June 2017.
Tuesday, 17 October 2017 09:42

CLINUVEL Newsletter - October 2017

Tuesday, 10 October 2017 17:42

CLINUVEL CONFIRMS AGM DATE

CLINUVEL CONFIRMS AGM DATE Leatherhead, UK and Melbourne, Australia, 10 October 2017 CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION: CLVLY; XETRA-DAX: UR9] today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017 at 10.00am AEDT at Arnold Bloch Leibler, Level 21, 333 Collins Street, Melbourne, Victoria, Australia 3000. A formal Notice of Meeting and the Company’s Annual Report will be lodged with the ASX no later than 27 October 2017.- End - About CLINUVEL PHARMACEUTICALS LIMITED CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical…
Wednesday, 04 October 2017 17:59

ELIE ISHAG TO RETIRE FROM CLINUVEL BOARD

ELIE ISHAG TO RETIRE FROM CLINUVEL BOARDMelbourne, Australia and Leatherhead, UK, 04 October 2017 CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION: CLVLY; XETRA-DAX: UR9] today announced that Mr Elie Ishag has advised that he will not stand for re-election as Non-Executive Director of CLINUVEL at the Company’s 2017 Annual General Meeting. He will continue to serve on the Board of CLINUVEL until the date of the Meeting. Mr Ishag has been a shareholder of the Company for 12 years and has served on the Board of Directors since February 2011. He has been a member of the Remuneration Committee…
CLINUVEL TO SUBMIT EUROPEAN POST-MARKETING DATA AS PART OF NDA FOR EPPMelbourne, Australia and Leatherhead, UK, 19 September 2017 EUROPEAN POST-MARKETING SAFETY DATA TO BE SUBMITTED AS PART OF NEW DRUG APPLICATION (NDA), EXPECTED IN DECEMBER 2017 NO RISK EVALUATION & MITIGATION STRATEGIES (REMS) EXPECTED BUT A SIMILAR POST-MARKETING PROGRAM AS IN EUROPE FDA ANSWER IS EXPECTED TO THE REQUEST FOR PRIORITY REVIEW FAST TRACK = ROLLING REVIEW CLINUVEL PHARMACEUTICALS LTD [ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION: CLVLY; XETRA-DAX: UR9] today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to…
Wednesday, 06 September 2017 17:37

Appendix 3B

Wednesday, 09 August 2017 07:51

Form 604, 09 August 2017

Monday, 31 July 2017 16:51

Appendix 4C - Quarterly report

Melbourne, Australia, and Leatherhead, UK, 31 July 2017 The Appendix 4C lodged earlier today reported in item 4.2 a “Net cash from / (used in) operating activities” result of (4,626) for the current quarter. This number should read 4,626, as referred to in item 1.9. Furthermore, item 4.5 “Effect of movement in exchange rates on cash held” should read 375 for the current quarter, instead of (375). This has now been corrected and reflected in the Appendix 4C attached. - End -CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY), a global biopharmaceutical company focused on developing…

Quick Links